DOCSLIB.ORG

Familial Cardiomegaly by G

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Familial Cardiomegaly by G J Clin Pathol: first published as 10.1136/jcp.12.4.355 on 1 July 1959. Downloaded from J. clin. Path. (1959), 12, 355. FAMILIAL CARDIOMEGALY BY G. GARRETT,* W. J. HAY, AND A. G. RICKARDS From the Royal Lancaster Infirmary, Lancaster (RECEIVED FOR PUBLICATION SEPTEMBER 18, 1957) In 1949 William Evans gave the name of these criteria and include eight necropsy studies. familial cardiomegaly to what he believed to be a Only these cases are included in Table I and the "distinct syndrome having a definite clinical, subsequent discussion. cardiographic, and pathological pattern." The The purpose of this paper is to present a further essential features were the familial incidence example of a family with cardiomegaly, the three of cardiomegaly without obvious cause and a affected members of which died suddenly. Post- marked tendency to arrhythmia and heart block mortem studies were made in all three cases with associated palpitation, giddiness, and although in one details of the necropsy findings syncope. Death may be sudden or rapid due to are no longer available. the development of left ventricular failure. In the electrocardiogram the QRS complexes are often Case Histories exceptionally wide and the T waves inverted. Case 1.-G. D., a man aged 30 years at death, came Conspicuous myocardial fibrosis and hypertrophy home from work one evening in April, 1956, in his of the remaining muscle fibres are the striking usual good health, and while playing with his children copyright. pathological findings. Both the degree of in the garden suddenly collapsed and died. There conduction defect and the prognosis seem to was no history of rheumatic fever or other serious depend on the extent of myocardial fibrosis and illness in the past. Eight months before his death he cardiac sustained a slight injury to the right groin with enlargement. haematoma formation in the spermatic cord. His Evans referred to two previous accounts of wife thought that he was slow to pick up after that obscure cardiomegaly occurring in members of accident, but he eventually recovered, and his mother, http://jcp.bmj.com/ the same family published in the case records of who was with him on the day before he died, the Massachusetts General Hospital in 1942 and remarked that she thought he was in excellent health. by Addarii (1943) and Addarii, Martini, Mahaim, At no time was he heard to complain of dyspnoea, and Winston (1946). Subsequently cases have chest pain, faintness, or palpitation. been published by Davies (1952), Parsons (1952), Necropsy performed by one of us (A. G. R.) on the De Matteis and Ozzano (1954), Campbell and instructions of the coroner 21 hours after death revealed the following abnormalities. Turner-Warwick (1956), Gaunt and Lecutier was that of a well-built male with The body young on September 25, 2021 by guest. Protected (1956), and Paulley, Jones, Green, and Kane a previous appendicectomy scar; significant macro- (1956). Among these, however, are included cases scopic findings were confined to the thoracic cavity. of cardiomegaly with no supporting family The heart was markedly enlarged (weight 500 g.), the history and others where there is good reason hypertrophy mostly affecting the left ventricle, which to believe that the cardiac hypertrophy was in parts was nearly 2 cm. thick and appeared at first secondary to acquired valvular disease, congenital sight to be of the usual hypertensive type. On closer cardiac malformations, or toxoplasmosis. In our inspection it was seen that the outer part of the view the diagnosis of familial cardiomegaly myocardium consisted of pale fibrous tissue almost giving the impression of an outer shell surrounding should only be made when other causes of cardiac the inner layer (Fig. 1). Strands of fibrous tissue enlargement have been excluded and when there could be seen penetrating the deeper aspects of the is a clear supporting family history. Moreover, myocardium, but the predominantly peripheral in the present state of knowledge, it seems wise distribution was striking. The compact outer rim was only to include those cases where the diagnosis well demarcated from the rest of the myocardium has been established by necropsy study in at least except in the region of the interventricular septum one affected member of the family. The reports where its discrete pattern became replaced by diffuse of seven affected families (15 cases) comply with fibrotic mottling. The trabeculae carnae, papillary and chordae tendineae showed no evidence *Present address: Department of Clinical Pathology, Manchester muscles, Royal Infirmary. of fibrosis. The right ventricle and both auricles J Clin Pathol: first published as 10.1136/jcp.12.4.355 on 1 July 1959. Downloaded from 356 G. GARRETT, W. J. HAY, anid A. G. RICKARDS TABLE I MAIN CLINICAL FEATURES Age Length of Author's () History Necropsy No. Author Case Age Sex Family from No. at Relationship Symptoms Arrhythmias Heart Block Onset of IFindings Death Symptoms 2 Case records----A_ , I1l i (21)X4|l, M Brother with...:,t- con- Dyspnoea, Complete A-V 6 months Yes of M.G. gestive failure. fatigue, block Hosp. Sister with car- congestive (1942) diomegaly A-V failure UIU6CK anaI conl- gestive failure 2 Addarrii et al. I (?) M Brother of Case 3 Dyspnoea, Auricular Complete A-V 9 ,. (t943) syncope fibrillation block, brancli bundle block 3 Addarii et al. I (21) M Brother of Case 2. Dyspnoea, Auricular fibril- Complete A-V 15 years ,, ((1946) Mother died fatigue, lation, parox- block, branch C.C.F. and syn- syncope, ysmal tachy- bundle block cope congestive cardia failure 4 Evans (1949) I (18) M Son of Case 6. Giddiness. Paroxysmal Branch bundle 2 tooiths Brother of Case paroxysmal tachycardia, block 5 tachycardia extrasystoles 5 2 20 M Son of Case 6. Giddiness Auricular fibril- 6 ,, Brother of Case lation, parox- 4 ysmal auricu- lar tachycardia 6 3 43 F Mother of4 and 5. Syncope Auricular fibril- 12 years Three of her sib- lation, extra- lings believed systoles affected - 7 8 (16) M Son of Case 8 Sinus brady- 412 *s Yes cardia 8 App. 42 F Mother of Case 7 Paroxysmal, Paroxysmal Prolonged P-R 2 months tachycardia tachycardia interval, with occa- branch bundle sional block copyright. syncope 9 Gaunt and I (51) M Brother of Case I I Dyspnoea, Auricular Comple:e A-V 20 Yes Lecutier syncope fibrillation block (1956) 10 2 23 F' Daughter of Case Arthralgia, 3 ,, 1t1 slight 1,* . dyspnoea 11 3 (531) F Mother of Case 10. Syncope, Complete A-V 4 years - Sister of Case 9 dyspnoea block, branclh bundle block 12 Campbell and (23) M Son of Case 13 Syncope, Paroxysmal Prolonged P-R, 3 years Yes http://jcp.bmj.com/ Turner- palpitation, tachycardia, branch bundle Warwick dyspnoea, ventricular block (1956) severe chest extrasystoles pain 13 ,. ..1 2 (29) F Mother of Case 12l Dyspnoea, Branch bundle I year Eight of her 12 congestive block siblings died of failure, heart disease syncope under 40 years 14 3 (36) M Son of Case 15 Syncope Sinus and nodal Varying degrees 6 months Yes bradycardia, of A-V block, nodal or ven- branch bundle on September 25, 2021 by guest. Protected tricular extra- block systoles 15 4 66 F Mother of Case 14. Faintness, Paroxysmal Branch bundle 40 years Her sister, fatigue, auricular block mother, three dyspnoea flutter, aunts, and grand- sinus mother died of bradycardia heart disease appeared unaffected, and the pericardium and myocardium distributed peripherally and correspond- endocardium were also macroscopically normal. The ing to the area seen with the naked eye. The fibrous aorta merely showed slight atheroma of its first part, strands tended to separate the muscle fibres into and there was no evidence of coarctation. The lungs bundles (Fig. 2) and many of these isolated lobules of were engorged and the trachea and bronchi contained muscle showed degenerative changes similar to those a large amount of mucus; all the other organs, seen in early cell death following ischaemia (Fig. 3); including the brain and spinal cord, appeared normal slight infiltration with lymphocytes was seen in to the naked eye. occasional areas of fibrosis (Fig. 4). The right Microscopic examination of the left ventricle ventricle showed a similar pattern of interstitial showed marked hypertrophy of individual muscle fibrosis, although of lesser extent, and its distribution fibres associated with gross fibrosis of the was more irregular and was not confined to the J Clin Pathol: first published as 10.1136/jcp.12.4.355 on 1 July 1959. Downloaded from FAMILIAL CARDIOMEGALY 357 4, *4:::: FIG. copyright. http://jcp.bmj.com/ cv, FIG. 3 on September 25, 2021 by guest. Protected 12"IN~~~~~~*.* FIG. I.-Cross section of left ventricular wall showing peripheral ~~~~~~~~~~~~~~~~ w fibrotic mottling in Case 1. tFG. FIG. 2.-Trabeculated fibrosis of the left ventricle in Case 1. Haema- toxylin and eosin, x 60. FIG. 3.-Degenerative change in muscle fibres surrounded by fibrous tissue in Case 1. Haematoxylin and eosin, x 150. J Clin Pathol: first published as 10.1136/jcp.12.4.355 on 1 July 1959. Downloaded from 358 G. GARRETT, W. J. HAY, and A. G. RICKARDS papillary tips," but unfortunately the myo- cardium was not examined histologically. The coronary arteries were recorded as being normal. Various organs were examined for a wide variety of chemical poisons with negative results, death being eventually attributed to " acute pulmonary oedema precipitated by streptococcal pneumonia." From the description of the lungs and heart 41 it seems clear that in fact death was due to ... .. left ventricular failure. Case 3.-P. D., the sister of Cases 1 and 2, also died suddenly at the age of 18 years .......... * on December 26, 1939, exactly seven years before the death of her sister.
Load more

Recommended publications
  • Cardiac Involvement in COVID-19 Patients: a Contemporary Review
    Review Cardiac Involvement in COVID-19 Patients: A Contemporary Review Domenico Maria Carretta 1, Aline Maria Silva 2, Donato D’Agostino 2, Skender Topi 3, Roberto Lovero 4, Ioannis Alexandros Charitos 5,*, Angelika Elzbieta Wegierska 6, Monica Montagnani 7,† and Luigi Santacroce 6,*,† 1 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Coronary Unit and Electrophysiology/Pacing Unit, Cardio-Thoracic Department, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 2 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Cardiac Surgery, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] (A.M.S.); [email protected] (D.D.) 3 Department of Clinical Disciplines, School of Technical Medical Sciences, University of Elbasan “A. Xhuvani”, 3001 Elbasan, Albania; [email protected] 4 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 5 Emergency/Urgent Department, National Poisoning Center, Riuniti University Hospital of Foggia, 71122 Foggia, Italy 6 Department of Interdisciplinary Medicine, Microbiology and Virology Unit, University of Bari “Aldo Moro”, Piazza G. Cesare, 11, 70124 Bari, Italy; [email protected] 7 Department of Biomedical Sciences and Human Oncology—Section of Pharmacology, School of Medicine, University of Bari “Aldo Moro”, Policlinico University Hospital of Bari, p.zza G. Cesare 11, 70124 Bari, Italy; [email protected] * Correspondence: [email protected] (I.A.C.); [email protected] (L.S.) † These authors equally contributed as co-last authors. Citation: Carretta, D.M.; Silva, A.M.; D’Agostino, D.; Topi, S.; Lovero, R.; Charitos, I.A.; Wegierska, A.E.; Abstract: Background: The widely variable clinical manifestations of SARS-CoV2 disease (COVID-19) Montagnani, M.; Santacroce, L.
    [Show full text]
  • Cardiac Myofibroblasts Enhance Hypertrophy and Systolic Dysfunction, but Not Fibrosis in Experimental Autoimmune Myocarditis
    Cardiac myofibroblasts enhance hypertrophy and systolic dysfunction, but not fibrosis in experimental autoimmune myocarditis P­08.3­45 K. TkaczI, A. Jaźwa­KusiorII, F. RolskiI, E. DziałoI, K. WęglarczykI, M. CzepielI, M. SiedlarI, G. KaniaIII, P. BłyszczukI IJagiellonian University Medical College, Department of Clinical Immunology, Cracow, Poland, IIJagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of Medical Biotechnology, Cracow, Poland, IIIUniversity Hospital Zurich, Division of Rheumatology, Zurich, Switzerland Myocarditis is a common cause of dilated cardiomyopathy which is characterized by ventricular stiffening, cardiac fibrosis and heart failure. In experimental autoimmune myocarditis (EAM) susceptible mice are immunized with alpha myosin heavy chain (αMyHC) and complete Freund's adjuvant (CFA). CD4+ T cell­mediated acute cardiac inflammation is followed by fibrosis and systolic dysfunction. The aim was to investigate the role of fibroblasts and myofibroblasts in myocarditis and postinflammatory cardiomyopathy in EAM model. EAM was induced in BALB/c mice by immunization with αMyHC/CFA. We used reporter strains expressing EGFP under the type I collagen promoter and RFP under α­smooth muscle actin (αSMA) promoter and transgenic αSMA­TK mice with ganciclovir­inducible myofibroblasts ablation. Comparing unaffected heart, the number of cardiac fibroblasts (EGFP+) and the subset of myofibroblasts (EGFP+αSMA+) was unchanged at inflammatory (day 21) and fibrotic stages (day 40). EGFP+ fibroblasts were sorted from control and myocarditis­positive hearts (d21) and analyzed for the whole genome transcriptomics by RNA sequencing. Analysis of differentially expressed genes (min. 2x fold change, p value < 0.05) suggested activation of immune processes (mainly chemokine production), response to stress, cytoskeletal and extracellular matrix re­organization in cardiac fibroblasts in response to myocarditis.
    [Show full text]
  • Mitral Valve Disease in Dogs- Truly Epic Kristin Jacob, DVM, DACVIM CVCA Cardiac Care for Pets Towson, MD
    Mitral Valve Disease in Dogs- Truly Epic Kristin Jacob, DVM, DACVIM CVCA Cardiac Care for Pets Towson, MD Chronic degenerative mitral valvular disease (DMVD) is the most common heart disease in dogs. In dogs with congestive heart failure, 75% have mitral regurgitation/degenerative valvular disease. Almost all have tricuspid regurgitations as well, but clinically the mitral regurgitation is the most significant. Degenerative valvular disease is most common in small breed dogs and more common in males than females. DMVD has been proven to be inherited in the Cavalier King Charles Spaniel and the Dachshund but several other breeds are predisposed, such as Bichons, poodles, Chihuahuas, Miniature Schnauzers, Boston Terriers. The cause of degenerative valvular disease remains unknown. However, the valve changes occur due to a destruction of collagen, deposition of mucopolysaccharide in the spongiosa and fibrosa layer of mitral valve, which also affects chordae tendinea. These changes prevent effective coaptation of the valve leaflets leading to progressive mitral regurgitation. Mitral regurgitation (MR) leads to decreasing forward output and increasing left atrial and left ventricular dilation and remodeling as well as activation of the neurohormonal systems. Typically, patients will have 2-3 years in asymptomatic phase (time between when heart murmur detected) until symptoms develop - congestive heart failure (CHF). We can detect progressive heart enlargement 6-12 months prior to the development of CHF. This means that we have a fairly long time period to intervene with therapy and alter the progression of the disease - we know what’s coming! Eventually left atrial pressure increases sufficiently and pulmonary congestion develops leading to symptoms of CHF and can also lead to pulmonary hypertension.
    [Show full text]
  • Prognostic Significance of Myocardial Fibrosis Quantification By
    Journal of the American College of Cardiology Vol. 56, No. 4, 2010 © 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.12.074 Cardiac Imaging Prognostic Significance of Myocardial Fibrosis Quantification by Histopathology and Magnetic Resonance Imaging in Patients With Severe Aortic Valve Disease Clerio F. Azevedo, MD, Marcelo Nigri, MD, Maria L. Higuchi, MD, Pablo M. Pomerantzeff, MD, Guilherme S. Spina, MD, Roney O. Sampaio, MD, Fla´vio Tarasoutchi, MD, Max Grinberg, MD, Carlos Eduardo Rochitte, MD São Paulo, Brazil Objectives We sought to determine whether the quantitative assessment of myocardial fibrosis (MF), either by histopathol- ogy or by contrast-enhanced magnetic resonance imaging (ce-MRI), could help predict long-term survival after aortic valve replacement. Background Severe aortic valve disease is characterized by progressive accumulation of interstitial MF. Methods Fifty-four patients scheduled to undergo aortic valve replacement were examined by ce-MRI. Delayed-enhanced images were used for the quantitative assessment of MF. In addition, interstitial MF was quantified by histologi- cal analysis of myocardial samples obtained during open-heart surgery and stained with picrosirius red. The ce- MRI study was repeated 27 Ϯ 22 months after surgery to assess left ventricular functional improvement, and all patients were followed for 52 Ϯ 17 months to evaluate long-term survival. Results There was a good correlation between the amount of MF measured by histopathology and by ce-MRI (r ϭ 0.69, p Ͻ 0.001). In addition, the amount of MF demonstrated a significant inverse correlation with the degree of left ventricular functional improvement after surgery (r ϭϪ0.42, p ϭ 0.04 for histopathology; r ϭϪ0.47, p ϭ 0.02 for ce-MRI).
    [Show full text]
  • Reversal of Maladaptive Fibrosis and Compromised Ventricular Function In
    Laboratory Investigation (2017) 97, 370–382 © 2017 USCAP, Inc All rights reserved 0023-6837/17 Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide Dorea Pleasant-Jenkins1,3, Charles Reese2,3, Panneerselvem Chinnakkannu1, Harinath Kasiganesan1, Elena Tourkina2, Stanley Hoffman2 and Dhandapani Kuppuswamy1 Chronic ventricular pressure overload (PO) results in congestive heart failure (CHF) in which myocardial fibrosis develops in concert with ventricular dysfunction. Caveolin-1 is important in fibrosis in various tissues due to its decreased expression in fibroblasts and monocytes. The profibrotic effects of low caveolin-1 can be blocked with the caveolin-1 scaffolding domain peptide (CSD, a caveolin-1 surrogate) using both mouse models and human cells. We have studied the beneficial effects of CSD on mice in which PO was induced by trans-aortic constriction (TAC). Beneficial effects observed in TAC mice receiving CSD injections daily included: improved ventricular function (increased ejection fraction, stroke volume, and cardiac output; reduced wall thickness); decreased collagen I, collagen chaperone HSP47, fibronectin, and CTGF levels; decreased activation of non-receptor tyrosine kinases Pyk2 and Src; and decreased activation of eNOS. To determine the source of cells that contribute to fibrosis in CHF, flow cytometric studies were performed that suggested that myofibroblasts in the heart are in large part bone marrow-derived. Two CD45+ cell populations were observed. One (Zone 1) contained CD45+/HSP47 − /macrophage marker+ cells (macrophages). The second (Zone 2) contained CD45moderate/HSP47+/macrophage marker − cells often defined as fibrocytes. TAC increased the number of cells in Zones 1 and 2 and the level of HSP47 in Zone 2.
    [Show full text]
  • Clinical Manifestation and Survival of Patients with I Diopathic Bilateral
    ORIGINAL ARTICLE Clinical Manifestation and Survival of Patients with Mizuhiro Arima, TatsujiI diopathicKanoh, Shinya BilateralOkazaki, YoshitakaAtrialIwama,DilatationAkira Yamasaki and Sigeru Matsuda Westudied the histories of eight patients who lacked clear evidence of cardiac abnormalities other than marked bilateral atrial dilatation and atrial fibrillation, which have rarely been dis- cussed in the literature. From the time of their first visit to our hospital, the patients' chest radio- graphs and electrocardiograms showed markedly enlarged cardiac silhouettes and atrial fibrilla- tion, respectively. Each patient's echocardiogram showed a marked bilateral atrial dilatation with almost normal wall motion of both ventricles. In one patient, inflammatory change was demonstrated by cardiac catheterization and endomyocardial biopsy from the right ventricle. Seven of our eight cases were elderly women.Over a long period after the diagnosis of cardiome- galy or arrhythmia, diuretics or digitalis offered good results in the treatment of edema and congestion in these patients. In view of the clinical courses included in the present study, we conclude that this disorder has a good prognosis. (Internal Medicine 38: 112-118, 1999) Key words: cardiomegaly, atrial fibrillation, elder women,good prognosis Introduction echocardiography. The severity of mitral and tricuspid regur- gitation was globally assessed by dividing into three equal parts Idiopathic enlargement of the right atrium was discussed by the distance from the valve orifice. The regurgitant jet was de- Bailey in 1955(1). This disorder may be an unusual congenital tected on color Doppler recording in the four-chamber view malformation. A review of the international literature disclosed and classified into one of the three regions (-: none, +: mild, that although several cases have been discussed since Bailey's ++:moderate, +++: severe).
    [Show full text]
  • Cardiac Fibrosis in Patients with Atrial Fibrillation: Mechanisms and Clinical Implications У
    Author's Accepted Manuscript У Cardiac fibrosis in patients with atrial М fibrillation: Mechanisms and clinical Г implications р Г Mikhail S. Dzeshka, MD, Gregory Y.H. Lip, MD, Viktor Snezhitskiy, PhD, Eduard Shantsila, PhD Journal of the American College of Cardiology й Volume 66, Issue 8, August 2015, P. 943-959 DOI: 10.1016/j.jacc.2015.06.1313 и р о т и з о п е Р STATE OF THE ART REVIEW Cardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implications У Mikhail S. Dzeshka MD1,2 М Gregory Y.H. Lip MD1,3 Viktor Snezhitskiy PhD2 Г Eduard Shantsila PhD1 р Г 1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, United Kingdom; 2Grodno State Medical University,й Grodno, Belarus; and 3Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. и р Total word count (including references,о figures legends, excluding tables and title page): 9,293 т Brief title: Cardiac fibrosis in иpatients with atrial fibrillation з Corresponding author:о Dr Eduard Shantsilaп , Tel: +44 121 507 5080, Fax: +44 121 554 4083, Email: [email protected] е Р 1 Competing interests G.Y.H.L. has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo and has been on the speakers bureau for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, У Microlife and Daiichi-Sankyo. M.S.D., V.S. and E.S. – none declared.М Г р Г й и р о т и з о п е Р 2 Abstract Atrial fibrillation (AF) is associated with structural, electrical and contractile remodeling of the atria.
    [Show full text]
  • Coronary Microvascular Dysfunction
    Journal of Clinical Medicine Review Coronary Microvascular Dysfunction Federico Vancheri 1,*, Giovanni Longo 2, Sergio Vancheri 3 and Michael Henein 4,5,6 1 Department of Internal Medicine, S.Elia Hospital, 93100 Caltanissetta, Italy 2 Cardiovascular and Interventional Department, S.Elia Hospital, 93100 Caltanissetta, Italy; [email protected] 3 Radiology Department, I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy; [email protected] 4 Institute of Public Health and Clinical Medicine, Umea University, SE-90187 Umea, Sweden; [email protected] 5 Department of Fluid Mechanics, Brunel University, Middlesex, London UB8 3PH, UK 6 Molecular and Nuclear Research Institute, St George’s University, London SW17 0RE, UK * Correspondence: [email protected] Received: 10 August 2020; Accepted: 2 September 2020; Published: 6 September 2020 Abstract: Many patients with chest pain undergoing coronary angiography do not show significant obstructive coronary lesions. A substantial proportion of these patients have abnormalities in the function and structure of coronary microcirculation due to endothelial and smooth muscle cell dysfunction. The coronary microcirculation has a fundamental role in the regulation of coronary blood flow in response to cardiac oxygen requirements. Impairment of this mechanism, defined as coronary microvascular dysfunction (CMD), carries an increased risk of adverse cardiovascular clinical outcomes. Coronary endothelial dysfunction accounts for approximately two-thirds of clinical conditions presenting with symptoms and signs of myocardial ischemia without obstructive coronary disease, termed “ischemia with non-obstructive coronary artery disease” (INOCA) and for a small proportion of “myocardial infarction with non-obstructive coronary artery disease” (MINOCA). More frequently, the clinical presentation of INOCA is microvascular angina due to CMD, while some patients present vasospastic angina due to epicardial spasm, and mixed epicardial and microvascular forms.
    [Show full text]
  • 1 the Role of Myocardial Fibrosis in Determining the Success Rate Of
    The role of myocardial fibrosis in determining the success rate of ablation for the treatment of atrial fibrillation Subothini Selvendran BSc (Hons) 1*, Nikhil Aggarwal BSc (Hons)1*, Justin Li 2, Gary Tse MBBS, MPH, PhD, FESC, FACC 3, Vassilios S Vassiliou MA, MBBS, MRCP, PhD, FHEA, FESC 1,4 Author Affiliations: 1 Royal Brompton Hospital and Imperial College London, UK 2 Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, P.R. China 3 Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, SAR, P.R. China; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, SAR, P.R. China; School of Health Sciences, University of Manchester, United Kingdom ([email protected]) 4 Norwich Medical School, University of East Anglia, Bob Champion Research & Education Building, James Watson Road, Norwich, UK; Royal Brompton Hospital and Imperial College London, UK *SS and NA contributed equally Corresponding Author Dr Vassilios S Vassiliou Norwich Medical School, University of East Anglia, Second Floor, Bob Champion Research & Education Building, James Watson Road, Norwich, UK Email: [email protected] 1 Introduction Atrial fibrillation (AF) is the commonest cardiac arrhythmia observed in clinical practice currently affecting 1-2% of the general population 1. With an increasing lifespan its prevalence will also increase. Whilst technological advances have resulted in earlier and easier diagnosis of AF even outside of the hospital setting, the appropriate selection of patients for specific pharmacotherapy or electrophysiological ablation procedures has not seen similar improvement.
    [Show full text]
  • Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease
    Advance Publication by J-STAGE Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease Javier D´ıez, MD, PhD*,** Although hypertensive heart disease (HHD) is clinically characterized by development of left ventricular hyper- trophy in the absence of a cause other than arterial hypertension, changes in the composition of myocardial tissue also develop in arterial hypertension, leading to structural remodeling of the myocardium (eg, fibrosis). Myo- cardial fibrosis is the major determinant of diastolic dysfunction/failure in patients with HHD. Recent available data on the determination of serum concentrations of collagen-derived serum peptides, as well as quantitative analysis of echoreflectivity to address the presence of fibrosis in the myocardium of hypertensive patients, are promising. In addition, preliminary data suggest that the goal of reducing myocardial fibrosis is achievable using specific pharmacological agents in patients with HHD. Key Words: Collagen; Fibrosis; Hypertension; Hypertrophy ypertensive heart disease (HHD) can be defined as cules, as a consequence of a number of pathologic processes the response of the heart to the stress imposed on mediated by mechanical, neurohormonal and cytokine H the left ventricle by progressively increasing arte- routes.11,12 Although an association has been found between rial pressure. HHD is characterized by complex changes in severe myocardial fibrosis and left ventricular (LV) systolic myocardial composition that are responsible for the struc- dysfunction in patients with
    [Show full text]
  • Case Report Chagas Cardiomyopathy Presenting As Symptomatic Bradycardia: an Underappreciated Emerging Public Health Problem in the United States
    Hindawi Case Reports in Cardiology Volume 2017, Article ID 5728742, 5 pages https://doi.org/10.1155/2017/5728742 Case Report Chagas Cardiomyopathy Presenting as Symptomatic Bradycardia: An Underappreciated Emerging Public Health Problem in the United States Richard Jesse Durrance,1 Tofura Ullah,1 Zulekha Atif,1 William Frumkin,2 and Kaushik Doshi1 1 Department of Internal Medicine, Jamaica Hospital Medical Center, 8900 Van Wyck Expressway, Jamaica, NY 11418, USA 2Department of Cardiology, Jamaica Hospital Medical Center, 8900 Van Wyck Expressway, Jamaica, NY 11418, USA Correspondence should be addressed to Richard Jesse Durrance; [email protected] Received 13 February 2017; Accepted 18 July 2017; Published 16 August 2017 Academic Editor: Aiden Abidov Copyright © 2017 Richard Jesse Durrance et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chagas cardiomyopathy (CCM) is traditionally considered a disease restricted to areas of endemicity. However, an estimated 300,000 people living in the United States today have CCM, of which its majority is undiagnosed. Wepresent a case of CCM acquired in an endemic area and detected in its early stage. A 42-year-old El Salvadoran woman presented with recurrent chest pain and syncopal episodes. Significant family history includes a sister inEl Salvador who also began suffering similar episodes. Physical exam and ancillary studies were only remarkable for sinus bradycardia. The patient was diagnosed with symptomatic sinus bradycardia and a pacemaker was placed. During her hospital course, Chagas serology was ordered given the epidemiological context from which she came.
    [Show full text]
  • Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis
    JACC: CARDIOVASCULAR IMAGING VOL. 12, NO. 2, 2019 ª 2019 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE (http://creativecommons.org/licenses/by/4.0/). FOCUS ISSUE: IMAGING IN AORTIC STENOSIS: PART II STATE-OF-THE-ART PAPER Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis a b a c Rong Bing, MBBS, BMEDSCI, João L. Cavalcante, MD, Russell J. Everett, MD, BSC, Marie-Annick Clavel, DVM, PHD, a a David E. Newby, DM, PHD, DSC, Marc R. Dweck, MD, PHD ABSTRACT Aortic stenosis is characterized both by progressive valve narrowing and the left ventricular remodeling response that ensues. The only effective treatment is aortic valve replacement, which is usually recommended in patients with severe stenosis and evidence of left ventricular decompensation. At present, left ventricular decompensation is most frequently identified by the development of typical symptoms or a marked reduction in left ventricular ejection fraction <50%. However, there is growing interest in using the assessment of myocardial fibrosis as an earlier and more objective marker of left ventricular decompensation, particularly in asymptomatic patients, where guidelines currently rely on non- randomized data and expert consensus. Myocardial fibrosis has major functional consequences, is the key pathological process driving left ventricular decompensation, and can be divided into 2 categories. Replacement fibrosis is irreversible and identified using late gadolinium enhancement on cardiac magnetic resonance, while diffuse fibrosis occurs earlier, is potentially reversible, and can be quantified with cardiac magnetic resonance T1 mapping techniques. There is a substantial body of observational data in this field, but there is now a need for randomized clinical trials of myocardial imaging in aortic stenosis to optimize patient management.
    [Show full text]